Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study
{{output}}
Background: Ublituximab is a glycoengineered monoclonal antibody that effectively reduces multiple sclerosis (MS) relapses but carries a significant risk of infusion-related reactions (IRRs), which is relatively higher than that ... ...
